Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150074 | 0.84 | MGLL (0.51) | MGLLSETD7VEGFAEGLN1TP53 | |
| SCHEMBL20151870 | 0.79 | MGLL (0.48) | MGLLSETD7VEGFAEGLN1TP53 | |
| SCHEMBL20151802 | 0.78 | MGLL (0.83) | MGLL | |
| SCHEMBL20150075 | 0.78 | MGLL (0.47) | MGLLSETD7VEGFAEGLN1TP53 | |
| SCHEMBL20151756 | 0.78 | MGLL (0.71) | MGLL | |
| SCHEMBL17109170 | 0.77 | ALDH1A1 (0.58) | MGLLVEGFAEGLN1TP53ALDH1A1 | |
| SCHEMBL16577092 | 0.77 | ALDH1A1 (0.54) | MGLLSETD7VEGFAEGLN1TP53 | |
| SCHEMBL20150071 | 0.77 | MGLL (0.48) | MGLLVEGFAEGLN1TP53ACKR3 | |
| SCHEMBL19386351 | 0.77 | MGLL (0.48) | MGLLVEGFAEGLN1TP53ALDH1A1 | |
| SCHEMBL4502120 | 0.76 | VEGFA (0.49) | MGLLVEGFAEGLN1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885TLR8 4684/4885SETD7 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.